451 related articles for article (PubMed ID: 23737188)
1. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies.
Al-Mansour Z; Nelson BP; Evens AM
Curr Hematol Malig Rep; 2013 Sep; 8(3):173-83. PubMed ID: 23737188
[TBL] [Abstract][Full Text] [Related]
2. Post-transplant lymphoproliferative disorders.
Singavi AK; Harrington AM; Fenske TS
Cancer Treat Res; 2015; 165():305-27. PubMed ID: 25655616
[TBL] [Abstract][Full Text] [Related]
3. Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy.
Evens AM; Roy R; Sterrenberg D; Moll MZ; Chadburn A; Gordon LI
Curr Oncol Rep; 2010 Nov; 12(6):383-94. PubMed ID: 20963522
[TBL] [Abstract][Full Text] [Related]
4. Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations.
Jagadeesh D; Woda BA; Draper J; Evens AM
Curr Treat Options Oncol; 2012 Mar; 13(1):122-36. PubMed ID: 22241590
[TBL] [Abstract][Full Text] [Related]
5. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
Allen UD; Preiksaitis JK;
Clin Transplant; 2019 Sep; 33(9):e13652. PubMed ID: 31230381
[TBL] [Abstract][Full Text] [Related]
6. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.
Lim WH; Russ GR; Coates PT
Nephrology (Carlton); 2006 Aug; 11(4):355-66. PubMed ID: 16889577
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation reveals differences in the tumor microenvironment.
Overkamp M; Granai M; Bonzheim I; Steinhilber J; Schittenhelm J; Bethge W; Quintanilla-Martinez L; Fend F; Federmann B
Virchows Arch; 2021 Jun; 478(6):1135-1148. PubMed ID: 33324999
[TBL] [Abstract][Full Text] [Related]
8. How I treat posttransplant lymphoproliferative disorder.
Amengual JE; Pro B
Blood; 2023 Oct; 142(17):1426-1437. PubMed ID: 37540819
[TBL] [Abstract][Full Text] [Related]
9. Hodgkin-like posttransplant lymphoproliferative disorder in children: does it differ from posttransplant Hodgkin lymphoma?
Ranganathan S; Webber S; Ahuja S; Jaffe R
Pediatr Dev Pathol; 2004; 7(4):348-60. PubMed ID: 14564542
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic spectrum and EBV status of post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation.
Chen DB; Song QJ; Chen YX; Chen YH; Shen DH
Int J Hematol; 2013 Jan; 97(1):117-24. PubMed ID: 23255160
[TBL] [Abstract][Full Text] [Related]
11. Post-transplant lymphoproliferative disorders.
Dharnidharka VR; Webster AC; Martinez OM; Preiksaitis JK; Leblond V; Choquet S
Nat Rev Dis Primers; 2016 Jan; 2():15088. PubMed ID: 27189056
[TBL] [Abstract][Full Text] [Related]
12. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
Chen DB; Wang Y; Song QJ; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
[TBL] [Abstract][Full Text] [Related]
13. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation.
Taylor AL; Marcus R; Bradley JA
Crit Rev Oncol Hematol; 2005 Oct; 56(1):155-67. PubMed ID: 15979320
[TBL] [Abstract][Full Text] [Related]
14. Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options.
Végso G; Hajdu M; Sebestyén A
Pathol Oncol Res; 2011 Sep; 17(3):443-54. PubMed ID: 21193979
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic characteristics of post-transplant lymphoproliferative disorders.
Nalesnik MA
Recent Results Cancer Res; 2002; 159():9-18. PubMed ID: 11785849
[TBL] [Abstract][Full Text] [Related]
16. Posttransplant lymphoproliferative disorder.
Everly MJ; Bloom RD; Tsai DE; Trofe J
Ann Pharmacother; 2007 Nov; 41(11):1850-8. PubMed ID: 17940127
[TBL] [Abstract][Full Text] [Related]
17. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
Mentzer SJ; Perrine SP; Faller DV
Transpl Infect Dis; 2001 Sep; 3(3):177-85. PubMed ID: 11493400
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics of monomorphic post-transplant lymphoproliferative disorders.
Choi JH; Park BB; Suh C; Won JH; Lee WS; Shin HJ
J Korean Med Sci; 2010 Apr; 25(4):523-6. PubMed ID: 20357991
[TBL] [Abstract][Full Text] [Related]
19. Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56
Lam JKP; Azzi T; Hui KF; Wong AMG; McHugh D; Caduff N; Chan KH; Münz C; Chiang AKS
Front Immunol; 2020; 11():1231. PubMed ID: 32625211
[TBL] [Abstract][Full Text] [Related]
20. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
Ganne V; Siddiqi N; Kamaplath B; Chang CC; Cohen EP; Bresnahan BA; Hariharan S
Clin Transplant; 2003 Oct; 17(5):417-22. PubMed ID: 14703923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
